Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425436 | 0.90 | KDM1A (0.44) | DRD2DRD4KDM1AOPRD1OPRM1 | |
| SCHEMBL14938277 | 0.83 | KDM1A (0.49) | DRD2DRD4KDM1ACHRM4SIGMAR1 | |
| SCHEMBL14937747 | 0.82 | SLC5A7 (0.42) | DRD2DRD4KDM1A | |
| SCHEMBL530727 | 0.80 | FAAH (0.54) | KMT2A | |
| SCHEMBL425287 | 0.79 | HDAC1 (0.52) | DRD2DRD4OPRD1OPRM1CHRM4 | |
| SCHEMBL14937811 | 0.78 | FAAH (0.44) | — | |
| SCHEMBL14937999 | 0.78 | FAAH (0.43) | — | |
| SCHEMBL14938000 | 0.78 | FAAH (0.43) | — | |
| SCHEMBL7901870 | 0.78 | KDM1A (0.47) | DRD2DRD4KDM1AOPRD1OPRM1 | |
| SCHEMBL426575 | 0.77 | OPRD1 (0.50) | DRD2DRD4OPRD1OPRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | DRD2 1602/4885DRD4 2351/4885KDM1A 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.